Possible Interaction: Glucose and Pramlintide

“However, only preprandial injections of pramlintide (-15 and 0 min) were able to prevent the initial postprandial surge in glucose.”

“ Pramlintide infusion in the insulin‐treated patients resulted in statistically significant reductions in mean glucose , insulin, C‐peptide, and lactate concentrations during the 4‐h period after the Sustacal® test meal.”

“In humans, pramlintide slows gastric emptying and suppresses glucagon secretion during the prandial/postprandial period to slow and reduce the entry of glucose into the circulation.”

“The inhibition of endogenous glucose production by pramlintide was described using a sigmoidal function with capacity and sensitivity parameter estimates of 0.995 for Imax and 23.8 pmol/L for IC50.”

“ Pramlintide decreases postprandial glucose by lowering inappropriate postmeal glucagon secretion, slowing gastric emptying, and increasing satiety.”

“ Pramlintide reduces the increase in plasma glucagon that occurs following a meal in individuals with diabetes, and may thereby suppress inappropriate stimulation of liver glucose production.”

“ Pramlintide reduced incremental area …)) for glucagon and glucose versus placebo (glucagon: 15-microg dose, 4 +/- 7 pg(*)h/mL; 30-microg dose, 5 +/- 7 pg(*)h/mL; placebo, 35 +/- … dose, 129 +/- 43 mg(*)h/dL; 30-microg dose, 132 +/- 37 mg(*)h/dL; placebo, 217 +/- 56 mg(*)h/dL).”

“ Pramlintide has been shown to reduce the day-to-day fluctuations in glucose values that are commonly seen despite maximized insulin therapy alone.”

“ Pramlintide , a synthetic analogue of the beta‐cell hormone amylin, regulates the appearance of glucose in the circulation following meals through several mechanisms of action: slowing gastric emptying, preventing inappropriate postprandial secretion of glucagon and increasing satiety.”

“However, pramlintide reduced the post-prandial increase in glucose and glucagon levels (Fig. 1).”